Free tool
FAERS Monitor: Truvada
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021752 or its brand name (Truvada, Emtricitabine, Tenofovir Disoproxil Fumarate). Reports on generic versions are filed under their own applications.
Reports
45,437
Serious
38,317
84% of reports
Hospitalization
7,641
Death reported
1,835
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- bone density decreased16,618
- chronic kidney disease10,394
- osteonecrosis9,164
- bone loss9,115
- renal failure9,049
- multiple fractures8,191
- tooth loss8,163
- renal injury8,010
- osteoporosis7,326
- skeletal injury7,181
- pain6,586
- emotional distress6,351
- anxiety5,946
- anhedonia5,607
- osteopenia3,954
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 150 |
| 2006 | 395 |
| 2007 | 518 |
| 2008 | 906 |
| 2009 | 1,204 |
| 2010 | 1,078 |
| 2011 | 986 |
| 2012 | 1,141 |
| 2013 | 1,243 |
| 2014 | 1,476 |
| 2015 | 1,661 |
| 2016 | 1,419 |
| 2017 | 1,295 |
| 2018 | 1,667 |
| 2019 | 2,994 |
| 2020 | 14,655 |
| 2021 | 4,707 |
| 2022 | 2,977 |
| 2023 | 1,589 |
| 2024 | 1,567 |
| 2025 | 1,346 |
| 2026 | 462 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,008,722 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| skeletal injurySignal | 7,181 | 1047.1 | 1005.3 | 2,299,633 |
| bone lossSignal | 9,115 | 710.3 | 688.4 | 2,547,203 |
| bone density decreasedSignal | 16,618 | 521.0 | 510.6 | 4,061,204 |
| multiple fracturesSignal | 8,191 | 458.9 | 445.7 | 1,879,523 |
| tooth lossSignal | 8,163 | 299.7 | 292.0 | 1,475,839 |
| osteonecrosisSignal | 9,164 | 178.7 | 174.7 | 1,169,493 |
| renal injurySignal | 8,010 | 170.4 | 166.4 | 987,035 |
| osteopeniaSignal | 3,954 | 162.7 | 157.1 | 470,277 |
| anhedoniaSignal | 5,607 | 125.2 | 121.8 | 544,354 |
| osteoporosisSignal | 7,326 | 100.1 | 97.8 | 591,820 |
| chronic kidney diseaseSignal | 10,394 | 73.2 | 71.8 | 641,195 |
| renal failureSignal | 9,049 | 33.8 | 33.1 | 269,875 |
| emotional distressSignal | 6,351 | 25.6 | 25.0 | 142,890 |
| anxietySignal | 5,946 | 9.9 | 9.6 | 46,956 |
| painSignal | 6,586 | 5.0 | 4.9 | 21,511 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.